Refractory Solid Tumors
Pipeline by Development Stage
Drug Modality Breakdown
Oncology is a $53.9B market in consolidation, dominated by a handful of megacap players with blockbuster franchises approaching patent expiration.
Key Trends
- Heavy patent cliff exposure (REVLIMID $3.9B LOE 2028, JAKAFI $1.9B LOE 2028)
- Kinase inhibitors and immunomodulatory agents dominate spend; limited diversification in top 10
- Clinical trial volume remains exceptionally high (29,145 trials) but concentration in Phase 1-2 signals early-stage pipeline challenges
Career Verdict
Strong near-term opportunity for R&D and medical affairs roles, but competitive landscape and patent cliff urgency favor specialists over generalists.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 34% | Launch | Stable | 15.0yr |
| 2 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 8% | Peak | Stable | 15.4yr |
| 3 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 7% | LOE Approaching | Declining | 1.8yr |
| 4 | XTANDI (enzalutamide) | Astellas | $2.6B | 5% | Peak | Stable | 10.7yr |
| 5 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 4% | Peak | Stable | 8.9yr |
Drug Class Breakdown
concentrated in single product
single dominant product
multi-product class, competitive
facing near-term patent cliff
prostate cancer specialty
niche hematologic oncology
near-term LOE exposure
Career Outlook
StableOncology remains a premium therapeutic area but faces structural headwinds: top 10 products account for >80% of spend, patent cliffs loom (REVLIMID 2028), and late-stage pipeline thinness suggests slower near-term growth. However, high trial volume and consolidation create demand for specialized expertise in regulatory, clinical operations, and lifecycle management. Pharma professionals with kinase inhibitor, immunomodulatory, or ADC experience are in highest demand.
Breaking In
Entry-level candidates should target CROs (Thermo Fisher, IQVIA), emerging biotech (BeiGene, BeOne), or contract manufacturing; oncology specialization requires demonstrated domain knowledge.
For Experienced Professionals
Experienced professionals should focus on lifecycle/patent strategy roles (high salary, low headcount) or pivot to emerging modalities (ADCs, bispecifics) to avoid commoditization in crowded kinase inhibitor space.
In-Demand Skills
Best For
Hiring Landscape
Oncology hiring is actively concentrated at Thermo Fisher Scientific (CRO/CDMO services, 559 jobs), AstraZeneca (208 jobs), and emerging biotech players like BeiGene (185 jobs). Commercial roles dominate (412 jobs, $136K avg) but R&D positions offer the highest salary premium ($199K avg, 347 roles). Patent cliff urgency is creating acute demand for regulatory, CMC, and lifecycle management expertise.
Top Hiring Companies
By Department
Strong near-term hiring momentum, especially in CRO/CDMO and emerging biotech; Medical Affairs offers highest compensation but limited headcount.
On Market (1)
Approved therapies currently available
Competitive Landscape
7 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 23 trials with date data
Clinical Trials (25)
Total enrollment: 3,217 patients across 25 trials
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Irinotecan Study For Cervical Cancer
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
An Open-Label, Dose-Escalation Study of AZD2461
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors
Related Jobs in Oncology
Senior Accountant
Senior Analyst, Quality Control Microbiology – Microbial ID
Director, HTA, Evidence, and Global Access
Senior Director, R&D Quality Assurance (GCP-GLP-GvP)
Manager, Lab IT Support
Associate Director, Finance Systems & Processes
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.